The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
Arginine methyltransferase inhibitors and uses thereof
申请人:Epizyme, Inc.
公开号:US09365527B2
公开(公告)日:2016-06-14
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
[EN] COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS D'ITPKB
申请人:IRM LLC
公开号:WO2009123948A3
公开(公告)日:2009-11-26
US9365527B2
申请人:——
公开号:US9365527B2
公开(公告)日:2016-06-14
[EN] ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ARGININE MÉTHYLTRANSFÉRASE ET UTILISATIONS DE CEUX-CI
申请人:EPIZYME INC
公开号:WO2014153100A2
公开(公告)日:2014-09-25
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.